Warning: Undefined array key "network" in /hshare1/ZETTAI_path_WA_slash_usr_slash_proj_KARA/usr/proj/tcng/htdocs/tcng.php on line 565
Edge
EIF4EBP1 → CDK4
Networks Including this Edge
| GSE12627_top8000 - GSE12627 - SiGN-BN NNSR | Non-supervised hierarchical clustering of gene expression data |
| GSE10327_egf1520 - GSE10327 - SiGN-BN HC+Bootstrap | mRNA expression data of 62 human medulloblastoma tumors |
| GSE10890_egf1520 - GSE10890 - SiGN-BN HC+Bootstrap | mRNA Breast Cancer Cell Line Profiles |
| GSE12627_egf1520 - GSE12627 - SiGN-BN HC+Bootstrap | Non-supervised hierarchical clustering of gene expression data |
| GSE12667_egf1520 - GSE12667 - SiGN-BN HC+Bootstrap | Discovery of somatic mutations in lung adenocarcinomas |
| GSE14814_egf1520 - GSE14814 - SiGN-BN HC+Bootstrap | Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer |
| GSE15395_egf1520 - GSE15395 - SiGN-BN HC+Bootstrap | HCT116 tumor cells treated with a CDK inhibitor |
| GSE19188_egf1520 - GSE19188 - SiGN-BN HC+Bootstrap | Expression data for early stage NSCLC |
| GSE24080_egf1520 - GSE24080 - SiGN-BN HC+Bootstrap | MAQC-II Project: Multiple myeloma (MM) data set |
| GSE25065_egf1520 - GSE25065 - SiGN-BN HC+Bootstrap | Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25066_egf1520 - GSE25066 - SiGN-BN HC+Bootstrap | Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE26599_egf1520 - GSE26599 - SiGN-BN HC+Bootstrap | Gene expression profile in response to doxorubicin-rapamycin combined treatment of HER-2 overexpressing human mammary epithelial cell lines |
| GSE2912_egf1520 - GSE2912 - SiGN-BN HC+Bootstrap | Molecular classification of multiple myeloma |
| GSE29683_egf1520 - GSE29683 - SiGN-BN HC+Bootstrap | Coexpression of Normally Incompatible Developmental Pathways in Retinoblastoma Genesis [human tumor/cell line data] |
| GSE4581_egf1520 - GSE4581 - SiGN-BN HC+Bootstrap | Gene Expression Profiles of Multiple Myeloma (N=414) Before Treatment |
| GSE5460_egf1520 - GSE5460 - SiGN-BN HC+Bootstrap | Predicting Features of Breast Cancer with Gene Expression Patterns |
| GSE5900_egf1520 - GSE5900 - SiGN-BN HC+Bootstrap | Gene Expression of Bone Marrow Plasma Cells from Healthy Donors (N=22), MGUS (N=44), and Smoldering Myeloma (N=12) |
| GSE6365_egf1520 - GSE6365 - SiGN-BN HC+Bootstrap | Distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma |
| GSE6401_egf1520 - GSE6401 - SiGN-BN HC+Bootstrap | Up-regulation of translational machinery and distinct genetic subgroups characterize hyperdiploidy in multiple myeloma |
| GSE6956_egf1520 - GSE6956 - SiGN-BN HC+Bootstrap | Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men |
| GSE7904_egf1520 - GSE7904 - SiGN-BN HC+Bootstrap | Expression data from human breast tissue |
| GSE8546_egf1520 - GSE8546 - SiGN-BN HC+Bootstrap | Gene Expression Changes in Myeloma Cells Following Short Term In-vivo Drug Exposure |
